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Key Points
• Recruitment of STXBP1 by
Slp4-a promotes Weibel-
Palade body exocytosis.
• Ex vivo EIEE4 endothelial
cells haploinsufficient for
STXBP1 have impaired
Weibel-Palade body
exocytosis.
Vascular endothelial cells contain unique rod-shaped secretory organelles, called Weibel-
Palade bodies (WPBs), which contain the hemostatic protein von Willebrand factor (VWF)
and a cocktail of angiogenic and inflammatory mediators. We have shown that the Rab27A
effector synaptotagmin-like protein 4-a (Slp4-a) plays a critical role in regulating hormone-
evoked WPB exocytosis. Using a nonbiased proteomic screen for targets for Slp4-a, we
now identify syntaxin-binding protein 1 (STXBP1) and syntaxin-2 and -3 as endogenous
Slp4-a binding partners in endothelial cells. Coimmunoprecipitations showed that STXBP1
interacts with syntaxin-2 and -3, but not with syntaxin-4. Small interfering RNA-mediated
silencing of STXBP1expression impaired histamine- and forskolin-inducedVWFsecretion.
To further substantiate the role of STXBP1, we isolated blood outgrowth endothelial cells
(BOECs) from an early infantile epileptic encephalopathy type 4 (EIEE4) patient carrying a
de novo mutation in STXBP1. STXBP1-haploinsufficient EIEE4 BOECs contained similar
numbers of morphologically normal WPBs compared with control BOECs of healthy donors; however, EIEE4 BOECs displayed
significantly impaired histamine- and forskolin-stimulated VWF secretion. Based on these findings, we propose that the Rab27A–Slp4-
acomplexonWPBpromotesexocytosis throughan interactionwithSTXBP1, therebycontrolling thereleaseofvaso-activesubstances in
the vasculature. (Blood. 2014;123(20):3185-3194)
Introduction
Endothelial cells line the lumen of all blood vessels, providing
a highly dynamic barrier that plays a crucial role in maintaining
vascular homeostasis. They contain specialized secretory organ-
elles called Weibel-Palade bodies (WPBs) that allow the endothelium
to store and release, in a regulated fashion, a presynthesized cocktail of
hemostatic, inﬂammatory, and angiogenic mediators in response to
endothelial activation, injury, or stress.1-3 The main component of
these organelles is von Willebrand factor (VWF), a multimeric
glycoprotein crucial for platelet plug formation and stabilizing
coagulation factor VIII. In addition to VWF, several soluble chemo-
kines (eg, interleukin-6 [IL-6], IL-8) as well as the integral membrane
proteins CD63 and P-selectin are stored in these organelles.4-9
Coordinated expression of CD63 and P-selectin on the endo-
thelial cell surface after WPB exocytosis is crucial for leu-
kocyte extravasation at sites of inﬂammation.10 The presence of
angiopoietin-2 and insulin-like growth factor-binding protein 7 in
WPBs points toward a critical role for the organelle in regulation of
angiogenesis.11-13
The precise composition of mediators stored in WPBs depends
crucially on the physical, mechanical, and chemical signals in the
local microenvironment; for example, targeting of eotaxin-3, IL-8,
and IL-6 has been observed in response to pro-inﬂammatory
mediators such as IL-1b or IL-4,5,7,14,15 whereas the inclusion of
angiopoietin-2 is modulated under conditions that mimic shear
stress.16
Exocytosis of WPBs is triggered by a wide range of physiological
secretagogues that trigger Ca21- and cyclic adenosine monophos-
phate (cAMP)-dependent signaling pathways, such as histamine and
thrombin or vasopressin and epinephrine, respectively.3,17-20 Several
key regulators of WPB exocytosis have been identiﬁed, including the
small guanosine triphosphates (GTPases) RalA, Rab3A, Rab3D,
and Rab27A.21-25 Rab27A plays a particularly crucial role in
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regulating WPB exocytosis through its ability to recruit multiple
effector molecules,26 including myosin Va-Rab interacting protein
(MyRIP), synaptotagmin-like protein 4-a (Slp4-a), andMunc13-4.
MyRIP-dependent recruitment of the actin motor protein myosin Va
to theWPB is proposed to link the organelle to the actin cytoskeleton,
preventing access to and fusion with the plasma membrane.27,28 In
contrast, both Slp4-a and Munc13-4 promote WPB exocytosis,25,29
although the mechanism remains unclear.
To investigate the mechanism by which Slp4-a regulates WPB
exocytosis, we used an unbiased mass spectrometry approach aimed
at identifying endogenous Slp4-a interactors in human endothelial
cells. Using this screen, we identiﬁed syntaxin binding protein 1
(STXBP1, also known as Munc18-1) and syntaxin-2 and -3 as
potential effectors of Slp4-a. RNA interference–mediated depletion
of STXBP1 signiﬁcantly impaired WPB release. Loss-of-function
mutations in STXBP1 have been shown to be the cause of early
infantile epileptic encephalopathy type 4 (EIEE4), a severe epileptic
disorder.30-32 Blood outgrowth endothelial cells (BOECs), isolated
from peripheral blood of a patient with EIEE4 carrying a de novo
mutation in STXBP1, displayed impaired stimulated WPB release,
providing further support for a role for STXBP1 in regulating VWF
secretion. Our ﬁndings provide a link between the Rab27A–Slp4-
a complex onWPBs and a regulatory component of the Soluble NSF
Attachment ProteinREceptor (SNARE) complex,which controls the
release of vaso-active substances in the vasculature.
Methods
Antibodies and reagents
Histamine, forskolin, 3-isobutyl-1-methylxanthine (IBMX), and ionomycin
were from Sigma-Aldrich (Steinheim, Germany). Glutathione-Sepharose 4B
was fromGEHealthcare Europe GmbH (Diegem, Belgium). Fetal calf serum
(FCS) was from Bodinco (Alkmaar, The Netherlands). Trypsin, Fura-2/AM,
and Alexa 488-, Alexa 568-, and Alexa 633-conjugated secondary antibodies
were from Invitrogen (Breda, The Netherlands). Primary antibodies used in
this study are shown in supplemental Table 1 on the Blood Web site. DNA
constructs are described in the supplemental data.
Cell culture, BOEC isolation, and secretion assay
Primary human umbilical vein endothelial cells (HUVECs) were obtained
from Promocell (Heidelberg, Germany) and were grown in EGM-2 medium
(Lonza, Basel, Switzerland) supplemented with 18% FCS (referred to hence-
forth as EGM-18) or as described.5 HEK293T cells were obtained from
ATCC (Wessel, Germany) and were grown in Dulbecco’s modiﬁed Eagle
mediumcontaining D-glucose, L-glutamine, and pyruvate (Life Technologies,
Bleiswijk, The Netherlands) supplemented with 10% FCS, 100 U/mL
penicillin, and 100 mg/mL streptomycin. BOECs were isolated as previously
described.33 Fifteen milliliters of venous blood was drawn from 1 individual
with EIEE4 and a de novo STXBP1mutation (patient 4 inDeprez et al30) after
the patient’s parents signed an informed consent form for participation. The
study was approved by the Sanquin Ethical Advisory Board and the Commi-
ssion forMedicalEthics of theUniversity ofAntwerp.The studywasconducted
in accordance with the Declaration of Helsinki. Cells were stimulated with
serum-free (SF)mediumorSFmediumcontaining 100mMhistamine or10mM
forskolin supplemented with 100 mM IBMX. VWF secretion was assayed by
enzyme-linked immunosorbent assay (ELISA) as described previously.19VWF
antigen levels in patient plasma were determined using ELISA.
RNA interference
Downregulation of endogenous expression of STXBP1 was performed es-
sentially as described.29 Pools of 4 small interfering RNA (siRNA) oligo
duplexes (ON-TARGETplus SMARTpool; Thermo Scientiﬁc, Rockford, IL)
were used to deplete HUVEC of STXBP1 (#L019571). A pool of 4 non-
targeting siRNAs (ON-TARGETplus nontargeting pool, #D001810) was
used as a control. Oligo sequences are given in supplemental Table 2.
Depletion of STXBP1 was assessed by immunoblot. Band intensities of
immunoblots were analyzed using ImageJ (http://rsbweb.nih.gov/ij/) to
determine STXBP1 knockdown efﬁciency.
Lentiviral transduction of endothelial cells. Lentivirus encoding
monomeric enhanced green ﬂuorescent protein (mEGFP) (LVX-mEGFP-
LIC) or mEGFP-STXBP1 (LVX-mEGFP-STXBP1) was produced in
HEK293T cells grown in a collagen matrix. LVX-mEGFP-LIC or LVX-
mEGFP-STXBP1 together with VSV-G, REV, and MDL helper plasmids34
were transfected using TransIT-LT1 transfection reagent (Mirus Bio LCC,
Madison, WI) essentially according to the manufacturer’s recommenda-
tion. After overnight incubation, the medium was exchanged for EGM-18.
Endothelial cells were transduced by 2 subsequent overnight incubations
with 0.45-mm ﬁltered EGM-18 culture supernatants of virus-producing
HEK293T cells.
Immunoprecipitation
HUVECs were lysed in NP40 lysis buffer (1%NP40, 10% glycerol, 137 mM
NaCl, 25mMN-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid, pH 7.4,
and protease/phosphate inhibitors), supplemented with 5 mM MgCl2 and
5 mM CaCl2 (STXBP1 and syntaxin-3 immunoprecipitations) or 10 mM
EDTA (GFP immunoprecipitation). Total cell lysates were centrifuged for
10minutes at 4°C at 20 000g. A total of 50mLmagnetic ProteinGDynabeads
was coupledwith 10mgmouse anti-STXBP1 immunoglobulinG (IgG)/rabbit
anti-syntaxin-3 IgG/sheep anti-GFP IgG or control mouse/rabbit/sheep
IgG (Santa Cruz Biotechnology, Santa Cruz, CA) and were subsequently
crosslinked using BS3 according to the manufacturer’s instructions. Super-
natants were incubated with antibody-coupled beads for 2 hours at 4°C and
were washed 4 times with 1% NP40 lysis buffer. Coimmunoprecipitates
and lysates were separated on precast 4% to 12% NuPAGE gels (Invitrogen)
and assessed by immunoblot with primary antibodies (supplemental Table 1),
followed by the appropriate infrared (IR) dye-coupled donkey secondary
antibodies (LI-CORBiosciences, Cambridge, UnitedKingdom).Membranes
were scanned with the LI-COR Odyssey Infrared Imaging system.
Fluorescence microscopy
Immunostaining and ﬂuorescence imaging of ﬁxed cells was performed as
previously described.5 Immunostained cells were mounted in MOWIOL or
Fluorsavemountingmedium (Calbiochem, Nottingham, UnitedKingdom) and
images were acquired by confocal microscopy using a Zeiss LSM 510 (Carl
Zeiss, Jena,Germany) or aLeica SP1 (LeicaMicrosystems,Wetzlar,Germany).
Ionomycin-induced exocytosis of WPBs containing Proregion-EGFP (which
essentially is VWF propeptide with a carboxy-terminal–fused EGFP tag35)
or EGFP-Slp4-a full length (FL) or EGFP-Slp4-a-synaptotagmin-like protein
homology domain (SHD) expressing WPBs was determined as previously
described.29,36 The probability of release (Pr) was determined as the mean
percentage of degranulation of ﬂuorescent WPBs after ionomycin stimulation.
Statistical analysis
Statistical analysis was by 1-way analysis of variance and Bonferroni posttest
analysis using GraphPad Prism 5.04 (GraphPad, La Jolla, CA). Signiﬁcance
values are shown in the ﬁgures or ﬁgure legends. Data are shown as mean6
standard error of the mean.
Results
N-terminal SHD mediates WPB localization but is not sufficient
to enhance WPB exocytosis
Previously, we have shown that Rab27A recruits its effector Slp4-a
to the WPB, which coincides with the acquisition of secretion
competence by this secretory organelle.29WPBs contain a cocktail of
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secretory Rabs capable of recruiting Slp4-a, including Rab27A and 3
isoforms of Rab3 (Rab3 A, B, and D).22,23,25,29 Slp4-a is reported to
bind to these secretory Rabs via its N-terminal SHD.37 We speculated
that this region was responsible for recruitment of Slp4-a toWPBs and
for this purpose we expressed epitope-tagged fusion proteins of Slp4-a
truncations that consist of, or lack, the SHD (Figure 1A). Full-length
mCherry-Slp4-a and mCherry-Slp4-a-SHD localized to WPBs,
whereas a truncation mutant lacking the SHD domain (mCherry-
Slp4-a-DSHD) did not. Instead, a diffuse cytoplasmic staining ex-
tending to the cell periphery and possibly the plasma membrane was
observed (Figure 1B).
Having conﬁrmed that the SHD domain of Slp4-a was essential
for recruitment to WPBs, we next examined whether this region
alone was sufﬁcient to support the enhancement of hormone-evoked
WPB exocytosis reported for EGFP-Slp4-a-FL.29 Exogenously ex-
pressed EGFP-Slp4-a-SHD labeled WPBs exclusively (Figure 2A).
Data from live cell imaging ofCa21-drivenWPBexocytosis in EGFP-
Slp4-a-SHD–expressing HUVEC (Figure 2B-D) was compared with
previously reported data for Proregion-EGFP (which labels the WPB
contents and serves as a control) and EGFP-Slp4-a FL–expressing
HUVECs.29 As for EGFP-Slp4-a FL, expression of EGFP-Slp4-a-
SHD signiﬁcantly increased the delay in the onset of WPB fusion
(Figure 2Di) and reduced the mean maximal rate of WPB exocytosis,
although like EGFP-Slp4-a FL, this difference did not reach statistical
signiﬁcance (Figure 2Dii). However, in contrast to EGFP-Slp4-a FL,
EGFP-Slp4-a-SHD failed to increase the Pr of WPBs (Figure 2Diii).
This suggested that the capacity to enhance Ca21-evoked WPB
exocytosis must reside in the region of the molecule distal to the SHD.
STXBP1 and syntaxin-2 and -3 are targets for Slp4-a in
endothelial cells
To identify effectors of Slp4-a involved in regulated WPB release,
we performed pull-downs in HUVEC lysates with glutathione
S-transferase (GST)-Slp4-a-DSHD and GST-Slp4-a-SHD. Putative
interacting proteins were identiﬁed by mass spectrometry after their
separation by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) and trypsin-mediated in-gel digestion (see
supplemental data). As expected, several peptides derived from
Slp4-a andGSTwere identiﬁed (Figure 3).Using the criteria outlined
in the supplemental data, 324 candidate binding partners for Slp4-a-
DSHD and 429 potential interactors for Slp4-a-SHD were identiﬁed
(for a full list, see supplemental Table 3A-B).
The SHD contains the WPB targeting signal for Slp4-a; there-
fore, we expect proteins responsible for recruitment of Slp4-a
among the candidates. Partners for the SHD were Rab8A and
Rab27A (Figure 3A), 2 Rab GTPases that have previously been
described to be able to interact with the SHD of Slp4-a.37,38 In-
terestingly, the Rac1 exchange factor PREX-1, which we recently
identiﬁed as a regulator of cAMP-mediated WPB release, was also
pulled down.39 Annotated spectra of Rab8A and Rab27A are
shown in supplemental Figures 1 and 2.
Because we determined that the exocytosis-promoting capacity
of Slp4-a is localized carboxyl-terminal of the SHD, we hypothe-
sized that among the interactome of Slp4-a, DSHD effectors of
Slp4-a involved in exocytosis can be found. A prominent binding
partner of Slp4-a-DSHDwas STXBP1 (Figure 3A). Seventeen unique
peptides corresponding to STXBP1 were identiﬁed; the annotated
Figure 1. Targeting of Slp4-a to WPBs depends on its Slp homology domain. (A) Cartoon overview of mCherry-tagged Slp4-a truncation variants, indicating the
boundaries of the SHD domain. (B) Immunocytochemical analysis of intracellular localization of Slp4-a variants. HUVECs were transfected with mCherry-tagged constructs
and fixed with paraformaldehyde 24 hours posttransfection. WPBs were visualized by immunostaining for VWF propeptide (green). Magnifications of boxed regions are shown
on the right and the bottom. Arrowheads point to WPBs devoid of mCherry-Slp4-a-DSHD. Bars represent 10 mm.
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spectrum of peptide ISEQTYQLSR corresponding to residues
288-297 is displayed in Figure 3B. STXBP1 has previously been
identiﬁed as an important regulator of secretory vesicle exocytosis
because of its abilities to regulate docking of secretory granules to
the plasma membrane and regulation of the SNARE complex
assembly.40-44 We also identiﬁed 2 SNARE proteins: 6 unique
peptides derived from syntaxin-3, and 1 peptide derived from
syntaxin-2. Other highly signiﬁcant candidates are Ras interacting
protein 1 and Vps39. Annotated spectra of syntaxin-2 and -3 are
shown in supplemental Figures 3 and 4.
Identiﬁcation of STXBP1, syntaxin-2, and syntaxin-3 as putative
binding partners of Slp4-a led us to test whether these proteins might
exist in a complex in which the interaction of syntaxin-2 or -3 with
Slp4-a is mediated through STXBP1, as has been previously
suggested.45 To conﬁrm the interaction of STXBP1 with syntaxins
and Slp4-a, we performed pull-down studies using exogenously
expressed mEGFP-STXBP1 in endothelial cells. As shown in
Figure 4A, STXBP1 bound endogenous Slp4-a as well as endog-
enous syntaxin-3. Further coimmunoprecipitation studies of endog-
enous STXBP1 revealed that syntaxin-2 and syntaxin-3 associate
with STXBP1 in HUVECs (Figure 4B). We also assessed the
ability of syntaxin-4 to interact with STXBP1, because this
syntaxin has previously been implicated in the regulation of WPB
exocytosis.46 However, syntaxin-4 failed to coimmunoprecipitatewith
STXBP1 (Figure 4B). When approached from the other end, we
could also demonstrate coprecipitation of STXBP1 with syntaxin-3
(Figure 4C). Syntaxin-3 immunoprecipitation did not coprecipitate
syntaxin-2, ruling out the possibility that STXBP1 binds syntaxin-2
Figure 2. Slp4-a enhances WPB probability of
release through a region distal to the SHD domain.
(A) HUVEC expressing EGFP-Slp4-a-SHD (green) and
immunolabeled for VWF (red). Grayscale images are
from the region indicated by the white box. Bar
represents 20 mm. (B) Fura-2 fluorescence ratio
showing a representative record of the increase in
fluorescence ratio (intracellular Ca21) upon addition of
1 mM ionomycin. (C) Cumulative plot of WPB fusion
times, normalized by their total number, in Proregion-
EGFP– (black), EGFP-Slp4-a FL– (gray), and EGFP-
Slp4-a-SHD–expressing cells (red). (Di-iii) Mean delays
(seconds), maximal rates of exocytosis (WPBs/second),
and probabilities of WPB exocytosis, Pr, (%) for Proregion-
EGFP– (black), EGFP-Slp4-a FL– (gray), and EGFP-
Slp4-a-SHD–expressing cells (red). Mean % degranula-
tion WPB Proregion-EGFP5 65.86 1.5% n5 46 cells,
2151 fusion events; mean % degranulation WPB EGFP-
Slp4-a FL 5 85.8 6 2.6%, n 5 15 cells, 849 fusion
events; mean % degranulation WPB EGFP-Slp4-a-
SHD 5 65.8 6 2.2%, n 5 22 cells, 694 fusion events.
*P , .05, ***P , .005
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and -3 simultaneously. Taken together, the data suggest that Slp4-a-
STXBP1-syntaxin-2 and Slp4-a-STXBP1-syntaxin-3 complexes
are present in endothelial cells.
STXBP1 depletion decreases WPB exocytosis
To address whether STXBP1 is involved in regulating WPB exo-
cytosis, we reduced STXBP1 in primary endothelial cells using
siRNA-mediated knockdown (Figure 5A). Endogenous expression
of STXBP1 protein was decreased to approximately 30% of control
levels (Figure 5B). STXBP1 depletion did not affect the number or
cellular localizationofWPBs (not shown), nor did it affect intracellular
levels of VWF (Figure 5C). Slp4-a or Rab27A localization was also
not notably altered after STXBP1 knockdown (not shown). However,
depletion of STXBP1 impaired both histamine- and forskolin-induced
VWF secretion (Figure 5D), indicating that STXBP1 is a critical
mediator for both Ca21- and cAMP-triggered WPB exocytosis.
Impaired WPB exocytosis in BOECs derived from an
EIEE4 patient
To further test the function of STXBP1 we determined whether
hormone-evoked secretion ofVWFwas impaired in endothelial cells
derived from a patient with a known defect in STXBP1. EIEE4 is
a rare and very severe epileptic disorder characterized by defective
neurotransmitter release as a consequence of de novo loss-of-
function mutations in the STXBP1 gene.30-32 As such, individuals
with EIEE4 represent human models of STXBP1 dysfunction. We
isolatedBOECs from a 16-year-old EIEE4 patient carrying a de novo
heterozygous 23- to 35.4-kbp microdeletion in STXBP1 [c.963 1?
(19671?)del; p.Thr322_Glu603 del].30 This deletion affects exons
12 to 20 of STXBP1 and is predicted to result in either a truncated
protein spanning amino acids 1-321 (provided that the messenger
RNA transcript undergoes translation) or in nonsense mediated decay,
which would result in haploinsufﬁciency.31 In this patient, circulating
plasma levels of VWF:Ag (64 IU/dL) were at the low end of the
physiological range (50-200 IU/dL). BOEC colonies were derived
from peripheral blood and were pooled for further analysis. As shown
in Figure 6A, endogenous STXBP1 protein expression was decreased
in EIEE4 BOECs compared with BOECs derived from a healthy
control individual (49.6 6 5.4% residual STXBP1 protein level as
estimated by immunoblotting, Figure 6B). Using 2 antibodies directed
against STXBP1, we were unable to detect the predicted truncated
form of STXBP1 in EIEE4 BOECs (data not shown), supporting the
hypothesis that the aberrant transcript is degraded. The decrease
in STXBP1 protein expression did not affect WPB morphology or
numbers as shown by immunocytochemistry (Figure 6C). In addition,
Figure 3. Proteomic identification of Slp4-a inter-
actors by pull-down of GST-tagged Slp4-a trunca-
tion variants. (A) Slp4-a interactors were pulled down
from HUVEC lysates by incubation with purified GST-
Slp4-a-SHD (left) or GST-Slp4-a-DSHD (right) coupled
to Glutathione-Sepharose. Eluted proteins were sepa-
rated by SDS-PAGE and analyzed by mass spectrom-
etry using the criteria described in the “Materials and
methods” section. Mascot score of putative interactors
(GST-Slp4-a-SHD: 429 identifications; GST-Slp4-a-
DSHD: 324 identifications) was plotted vs number of
unique peptides identified. Colored symbols indicate
putative interactors that have a ProHits frequency
#0.0278. Blue symbols represent bait (GST and
Slp4-a), green symbols represent interactors shown
in the table (bottom) that summarizes the Mascot score,
number of unique peptides identified, and the ProHits
frequency. (B) Annotated spectrum of the ISEQTYQLSR
peptide corresponding to residues 288-297 of STXBP1.
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we did not observe changes in the recruitment of Slp4-a or Rab27A to
WPBs (supplemental Figures 5 and 6), suggesting that the upstream
components of the exocytotic machinery were unperturbed. EIEE4
BOECs contained slightly more VWF when compared with healthy
donorBOECs; however, this differencewas not statistically signiﬁcant
(Figure 6D). We next tested whether agonist-induced release of VWF
was impaired in EIEE4 BOECs. Unstimulated (basal) VWF secretion
was slightly lower in EIEE4 BOECs, but this was not signiﬁcant
Figure 4. Interaction of STXBP1 with SNARE pro-
teins in endothelial cells. (A) Lysates of endothelial
cells lentivirally transduced with mEGFP-STXBP1 or
mEGFP were incubated with magnetic beads covalently
coupled with sheep anti-GFP IgG or an equivalent
amount of naive sheep IgG. Lysates (input) and coim-
munoprecipitates (IP) were separated by SDS-PAGE
and probed with rabbit anti-Slp4-a, anti-syntaxin-3, or
mouse anti-GFP followed by incubation with IR dye–
labeled donkey anti-rabbit or anti-mouse IgG. Slp4 a
and syntaxin-3 bound mEGFP-STXBP1 but not mEGFP.
(B,C) Endothelial lysates were incubated with magnetic
beads covalently coupled with mouse anti-STXBP1 IgG
or an equivalent amount of naive mouse IgG (B) or with
rabbit anti-syntaxin-3 IgG or an equivalent amount of
naive rabbit IgG (C). Lysates (input) and co- IP were
separated by SDS-PAGE and probed with rabbit anti-
STXBP1, anti-syntaxin-2, anti-syntaxin-3, or mouse anti-
syntaxin-4 followed by incubation with IR dye–labeled
donkey anti-rabbit or anti-mouse IgG. Syntaxin-2 and
syntaxin-3 but not syntaxin-4 coimmunoprecipitated with
STXBP1 (B). Immunoprecipitation of syntaxin-3 copre-
cipitated STXBP1 but not syntaxin-2 (C).
Figure 5. Impaired Ca21- and cAMP-mediated VWF
secretion after STXBP1 depletion. (A) HUVECs
were nucleofected with siRNA oligos directed against
STXBP1 (siSTXBP1) or with nonhybridizing control
oligos (siCTRL) and were assayed 48 hours after
nucleofection. Lysates were separated by SDS-PAGE
and were probed with rabbit anti-STXBP1 or mouse
anti-actin antibodies followed by incubation with IR
dye–labeled donkey anti-rabbit or anti-mouse IgG. (B)
Quantification of STXBP1 expression in control cells
(black) or after STXBP1 depletion (white) (n 5 3). (C)
Endothelial cells were lysed in SF medium containing
1% Triton X-100 and were assayed for VWF content by
ELISA (n 5 3). (D) Endothelial cells were incubated
for 30 minutes with SF medium (basal), SF medium
supplemented with 10 mM forskolin, and 100 mM IBMX
(FSK) or with 100 mM histamine (HIS). Supernatants
were assayed for secreted VWF by ELISA. ***P, .005
(n 5 3).
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compared with the control BOECs of a healthy donor. However, both
histamine- and forskolin-stimulated VWF secretion were signiﬁcantly
reduced in the EIEE4 BOECs compared with the control (Figure 6E).
Discussion
The small GTPase Rab27A and its effectors MyRIP, Munc13-4, and
Slp4-a play key roles as regulators of WPB exocytosis.25,27-29 Each
of these effectors performdiscrete steps in the sequence of events that
follow secretory organelle formation until eventual exocytosis, with
some of them exerting opposing effects (MyRIP-Myosin Va vs
Slp4-a and Munc13-4) on the probability of release of the WPB. A
complicated picture emerges, in which the releasability of a WPB is
determined by the balance of effectors present on itsmembrane29 and
the efﬁcacy of the individual effectors’ downstream mechanisms.
Although themechanism of action ofMyRIP, a negative-regulator of
WPB exocytosis, has been partially elucidated,28 how Slp4-a and
Munc13-4 function as positive regulators of WPB exocytosis remains
unclear. Here we provide evidence that Slp4-a functions through the
recruitment of STXBP1.
The SHD-domain of Slp4-a contains binding sites for several
secretory Rabs, including Rab27A, Rab3, and Rab8. Consistent with
this, our unbiased proteomic analysis identiﬁed Rab27A and Rab8A
as binding partners for the SHD domain of Slp4-a. Earlier work from
our group has shown that WPB localization of Slp4-a depends on
the small GTPases Rab27A and (primarily) Rab3B; however, only
Rab27A-bound Slp4-a was found to be functionally involved in
exocytosis. Surprisingly, we did not identify peptides of any of the
Rab3 isoforms in our pull-down with Slp4-a-SHD, although ﬂuo-
rescence recovery after photobleaching studies suggest that the
majority of WPB localized Slp4-a is in complex with Rab3B.29 The
likely explanation is that the Slp4-a–Rab3 interaction is weaker or
more labile than the corresponding interactions with Rab27A or
Rab8. This idea is supported by both coimmunoprecipitation studies
Figure 6. Impaired Ca21- and cAMP-mediated VWF
secretion in EIEE4 BOECs. (A) Healthy control donor
and EIEE4 BOEC lysates were separated by SDS-
PAGE and were probed with rabbit anti-STXBP1 or
mouse anti-actin antibodies followed by incubation with
IR dye–labeled donkey anti-rabbit or anti-mouse IgG.
(B) Quantification of STXBP1 expression in healthy
control donor (black) or EIEE4 BOECs (white) (n 5 3).
(C) EIEE4 and control donor BOECs were fixed
with paraformaldehyde and immunostained for VWF
(green) and VE-cadherin (red). Bar represents 10 mm.
(D) Endothelial cells were lysed in SF medium containing
1% Triton X-100 and lysates of healthy control donor
(black) or EIEE4 BOECs (white) were assayed for
VWF content by ELISA. (E) BOECs were incubated
for 30 minutes with SF medium (basal), SF medium
supplemented with 10 mM forskolin and 100 mM
IBMX (FSK), or with 100 mM histamine (HIS). Super-
natants were assayed for secreted VWF by ELISA.
***P , .005; n 5 3.
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that show a very weak pull-down of Rab3s compared with Rab27A
and by ﬂuorescence recovery after photobleaching analysis of WPB
dissociation rates for Slp4-a in the presence of exogenously ex-
pressed Rab27A, Rab3B, or Rab3D.29 In the latter case, the
dissociation rate for Slp4-a in the presence of Rab27A was an order
or magnitude slower than in the presence of Rab3B or Rab3D,
indicating a strong interaction between these molecules in living
cells. Similar observations have been made in PC12 cells; although
Rab3Awas shown to interact with Slp4-a in an in vitro binding assay
in the absence of Rab27A and Rab8A,38 only Rab27A and Rab8A
could be detected after coimmunoprecipitation with Slp4-a.47 The
strong interaction between Rab27A and Slp4-a might reﬂect in part
the unique ability of this Rab protein to bind Slp4-a irrespective of
its GTP/guanosine diphosphate status.37 Together, these properties
may have contributed to a competitive advantage for Rab27A during
our pull-down procedure. We also identiﬁed Rab8A in our screen,
a protein that is localized to theGolgi apparatus and is not recruited to
WPBs, which makes it an unlikely candidate to contribute directly to
WPB localization of Slp4-a.48 Rab8A-boundSlp4-a has been reported
to exert different effects on secretion depending on the cell type
studied.47,49,50 Nonetheless, depletion of Rab8A has been found to
decrease phorbol ester–inducedVWF release from endothelial cells48;
whether this is mediated via Slp4-a remains to be established.
Live cell imaging of WPB exocytosis in EGFP-Slp4-a-SHD–
expressing cells showed that the SHD domain of Slp4-a alone was
not sufﬁcient to enhance hormone-evoked WPB exocytosis. This
result suggests 2 items: (1) that the capacity of exogenously expressed
Slp4-a to promote WPB exocytosis is unlikely to be due solely to
displacement of the negative regulator MyRIP from the WPB,29 but
must instead reﬂect an active property of Slp4-a; and (2) that this
activity requires the region of the molecule distal to the SHD. We
identiﬁed STXBP1, syntaxin-2, and syntaxin-3 as endogenous mole-
cules that interact speciﬁcally with this distal region of Slp4-a.
STXBPs and syntaxins are key components of theSNAREmachinery,
a multiprotein complex that catalyzes the fusion of membranes.51
Our data suggest a crucial role for STXBP1 in both Ca21- and
cAMP-mediated VWF secretion from endothelial cells. In addition,
stimulated VWF secretion of BOECs derived from an EIEE4 patient,
a human model of STXBP1 haploinsufﬁciency, was impaired. Pre-
vious studies demonstrate that STXBP1 is essential for secretory
vesicle release, illustrated by the fact that STXBP1-null mutant mice
showed reduction of Ca21-regulated synaptic vesicle exocytosis from
neuroendocrine cells.42,43 Furthermore, insulin granule docking and
secretion from pancreatic b cells as well as catecholamine-containing
large, dense, core vesicle docking and secretion from chromafﬁn cells
are impaired by STXBP1 deletion.40,41,44 The severe neurological
defects displayed by patients with EIEE4 are also attributed to
abnormalities in synaptic vesicle release.30,31 On this basis, it is
likely that STXBP1 also contributes to the process ofWPBdocking in
endothelial cells, most likely by linking the WPB (through Rab27A–
Slp4-a) to plasma membrane syntaxins.
The physiological signiﬁcance of regulation of WPB exocytosis
by SNARE proteins is also underscored by a number of recent
genomewide association studies onVWFplasma levels and associated
risk factors for cardiovascular diseases such as arterial and venous
thrombosis. Single nucleotide polymorphisms in syntaxin-2 and also
STXBP5 (amember of the sameprotein family asSTXBP1) havebeen
associated with circulating VWF levels, risk of venous thrombosis,
and severity of the bleeding phenotype in vonWillebrand disease type
1 patients.52-55 It is intriguing to speculate that these deﬁcits reﬂect
disruption of the SNARE machinery regulating WPB exocytosis and
VWF secretion.
In the EIEE4 patient studied, plasma VWF levels were found to
be on the low side of the normal range. Such a mild quantitative
deﬁciency in VWF does not qualify as vonWillebrand disease type 1
according to current laboratory criteria,56 nor does it confer a high risk
of bleeding; indeed, this patient has no such history. Patients with
EIEE4 display severe neurological defects including early-onset epi-
lepsy and intellectual disability, which have been attributed to ab-
normalities in synaptic vesicle release.30,31 STXBP1 has also been
implicated in insulin release.40Althoughmoderately elevated levels of
blood glucose have been observed in mice heterozygous for STXBP1
deﬁciency as a result of slightly decreased insulin release,40 no altered
glucose levels or symptoms related to aberrant insulin secretion have
so far been reported in patientswithEIEE4.Circulating levels ofVWF
are determined primarily by unstimulated (basal) secretion of VWF
from endothelial cells, which is now known to arise primarily through
basalWPBexocytosis.57 It is interesting to speculatewhether the small
(but nonsigniﬁcant) reduction in basal secretion of VWF identiﬁed in
cultured BOECs isolated from the EIEE4 patient might reﬂect the
function of the patient’s own endothelium, accounting for a slightly
low circulating level of plasma VWF. However, we need to take into
consideration that it is difﬁcult to draw ﬁrm conclusions solely based
on BOEC data of a limited number of donors because signiﬁcant
heterogeneity seems to exist between single isolates.58 Furthermore,
based on our ﬁndings with EIEE4 BOECs, we hypothesize that the
Figure 7. Cartoon model of regulation of WPB
exocytosis. (I) Newly formed WPBs recruit Rab
proteins (Rab27A and Rab3A/B/D) and their effectors
Slp4-a, Munc13-4, and MyRIP/Myosin Va.22,23,25,27-29
(II) WPBs are anchored to the actin cytoskeleton via
Myosin Va and MyRIP.27,28 (III) STXBP1 links WPBs to
the SNAREs (syntaxin-2/3) via Slp4-a and Rab27A,
whereas STXBP3 (Munc18c) associates with syntaxin-4.46
(IV) SNARE complex assembly of syntaxins with WPB-
associated VAMP 3/8,59 potentially facilitated by Munc13-
4.25 Fusion of WPB and plasma membrane and dispersal
of WPB cargo into vascular lumen.
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effect of STXBP1haploinsufﬁciencyonVWFsecretionwouldpresent
itself more prominently upon acute endothelial stimulation (eg, after
administration with DDAVP).
A growing number of molecules have been identiﬁed as compo-
nents of the control mechanism for stimulated WPB exocytosis
(Figure 7). Earlier work from Fu and colleagues has shown the
involvement of Munc18c (STXBP3) and syntaxin-4 in thrombin-
stimulated P-selectin expression, which coincides with release of
a Munc18c–syntaxin-4 interaction after protein kinase C–dependent
phosphorylation events on either partner.46 Syntaxin-4 associates with
SNAP23 and the R-SNARE VAMP3 that, along with VAMP8 (which
does not associate with syntaxin-4), is localized on WPBs.59 From
these observations and ours, it becomes apparent that there is both
redundancywithin the SNAREmolecules involved aswell as a consid-
erable resilience of endothelial cells to conditions that perturb SNARE
complex formation.59,60 The apparent redundancy of SNARE com-
plexes operating in endothelial cells might allow for different upstream
signaling cascades to target discrete exocytotic machineries, providing
the endothelium with the possibility to ﬁne tune its secretory response.
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